{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:02:47Z","timestamp":1793980967548,"version":"4.8.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.critrevonc.2025.105097","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:59:45Z","timestamp":1766159985000},"page":"105097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A daily clinical practice decision-making overview for the present metastatic renal cell carcinoma (mRCC) management landscape"],"prefix":"10.1016","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0703-2959","authenticated-orcid":false,"given":"Sergio","family":"Bracarda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Sabbatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.105097_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2025.01.007","article-title":"Towards a consensus on the management of metastatic renal cell carcinoma: insights from a European Delphi Study","author":"Albiges","year":"2025","journal-title":"Eur. Urol. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105097_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105097_bib3","first-page":"517","article-title":"Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma","volume":"6","author":"Astore","year":"2023","journal-title":"Cancer Drug Resistance (Alhambra Calif)"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105097_bib4","article-title":"Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment","volume":"39","author":"Bahadoram","year":"2022","journal-title":"Giornale italiano di nefrologia: organo ufficiale della Societa italiana di nefrologia"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105097_bib5","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.annonc.2025.03.016","article-title":"Prospective randomized phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial","volume":"36","author":"Bergmann","year":"2025","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105097_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.euros.2021.12.007","article-title":"Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"37","author":"Bosma","year":"2022","journal-title":"Eur. Urol. Open Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105097_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020408","article-title":"Outcomes associated with first-line anti-PD-1\/ PD-L1 agents vs. sunitinib in patients with sarcomatoid renal cell carcinoma: a systematic review and meta-analysis","volume":"12","author":"Buonerba","year":"2020","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105097_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034626","article-title":"What is the optimum systemic treatment for advanced\/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis","volume":"10","author":"Cao","year":"2020","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105097_bib9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of renal cell carcinoma","volume":"75","author":"Capitanio","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.105097_bib10","doi-asserted-by":"crossref","first-page":"7321","DOI":"10.2147\/CMAR.S216605","article-title":"Pembrolizumab in combination with axitinib as first-line treatment for patients with renal cell carcinoma (RCC): evidence to date","volume":"12","author":"Chau","year":"2020","journal-title":"Cancer Manag. Res."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.105097_bib11","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1200\/JCO.2025.43.16_suppl.4505","article-title":"Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis from the phase 3 CheckMate 214 trial","volume":"43","author":"Choueiri","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.105097_bib12","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105097_bib13","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105097_bib14","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105097_bib15","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.3390\/ijms25073867","article-title":"Unlocking precision medicine: liquid biopsy advancements in renal cancer detection and monitoring","volume":"25","author":"Crocetto","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105097_bib16","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2015.06.042","article-title":"The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks","volume":"70","author":"Cumberbatch","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.105097_bib17","article-title":"Inter and intra-tumor heterogeneity of PD-L1 and MET expression in metastatic renal cell carcinoma (mRCC) - abstract 4569","volume":"15","author":"Derosa","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105097_bib18","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1080\/14712598.2021.1935856","article-title":"Pembrolizumab for the treatment of renal cell carcinoma","volume":"21","author":"Di Bona","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105097_bib19","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3390\/cancers17030436","article-title":"Immunotherapy-related hypophysitis: a narrative review","volume":"17","author":"Di Stasi","year":"2025","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105097_bib20","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.2337\/db13-0949","article-title":"Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity","volume":"63","author":"Dimas","year":"2014","journal-title":"Diabetes"},{"issue":"9605","key":"10.1016\/j.critrevonc.2025.105097_bib21","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet (London, England)"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105097_bib22","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105097_bib23","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s12325-021-02007-y","article-title":"Reviewing treatment options for advanced renal cell carcinoma: is there still a place for tyrosine kinase inhibitor (TKI) monotherapy?","volume":"39","author":"Fontes-Sousa","year":"2022","journal-title":"Adv. Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105097_bib24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/14737140.2023.2200170","article-title":"Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population","volume":"23","author":"Fujiwara","year":"2023","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105097_bib25","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40487-024-00305-3","article-title":"Understanding treatment decisions and management for patients with advanced renal cell carcinoma using hypothetical case studies: a vodcast","volume":"12","author":"Garmezy","year":"2024","journal-title":"Oncol. Ther."},{"key":"10.1016\/j.critrevonc.2025.105097_bib26","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.2147\/OTT.S145295","article-title":"Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma","volume":"10","author":"Gerendash","year":"2017","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.critrevonc.2025.105097_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/17562872211022870","article-title":"Second-line treatment in renal cell carcinoma: clinical experience and decision making","volume":"13","author":"Guadalupi","year":"2021","journal-title":"Ther. Adv. Urol."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.105097_bib28","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.2217\/fon.15.256","article-title":"Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis","volume":"11","author":"Guida","year":"2015","journal-title":"Future Oncol. (Lond. Engl.)"},{"key":"10.1016\/j.critrevonc.2025.105097_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.3207","article-title":"Efficacy of cabozantinib and nivolumab in cluster 1\/2 metastatic clear cell renal cell carcinoma: results from OPTIC RCC, a phase II trial of a novel RNAseq-based biomarker","author":"Haake","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105097_bib30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1477-7525-5-34","article-title":"Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index","volume":"5","author":"Harding","year":"2007","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.critrevonc.2025.105097_bib31","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105097_bib32","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.eururo.2024.02.014","article-title":"Avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma. the Tide-A phase 2 study","volume":"86","author":"Iacovelli","year":"2024","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105097_bib33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/24684570241303346","article-title":"Liquid biopsy for Renal Cell Carcinoma: a comprehensive review of techniques, applications, and future prospects","volume":"8","author":"Jani","year":"2024","journal-title":"Kidney Cancer (Clifton Va)"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105097_bib34","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0094-0143(03)00056-9","article-title":"Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease","volume":"30","author":"Janzen","year":"2003","journal-title":"Urol. Clin. North Am."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105097_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002724","article-title":"The influence of obesity-related factors in the etiology of renal cell carcinoma\u2014a mendelian randomization study","volume":"16","author":"Johansson","year":"2019","journal-title":"PLOS Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105097_bib36","article-title":"Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy","volume":"2","author":"Kwilas","year":"2015","journal-title":"Cancer Cell Microenviron."},{"key":"10.1016\/j.critrevonc.2025.105097_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221108685","article-title":"Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review","volume":"14","author":"Lalani","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105097_bib38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12943-023-01745-7","article-title":"Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application","volume":"22","author":"Li","year":"2023","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105097_bib39","first-page":"283","article-title":"Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas","volume":"36","author":"Lin","year":"2006","journal-title":"Ann. Clin. Lab. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105097_bib40","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur. Urol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105097_bib41","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1172\/JCI24612","article-title":"Rapid vascular regrowth in tumors after reversal of VEGF inhibition","volume":"116","author":"Mancuso","year":"2006","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105097_bib42","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/S1470-2045(24)00023-8","article-title":"Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology","volume":"25","author":"Marvaso","year":"2024","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105097_bib43","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1464-410X.2012.10946.x","article-title":"Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey","volume":"110","author":"Masini","year":"2012","journal-title":"BJU Int."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105097_bib44","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41585-024-00896-6","article-title":"Overall survival with adjuvant pembrolizumab in renal cell carcinoma - the shock of the lightning","volume":"21","author":"Massari","year":"2024","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.critrevonc.2025.105097_bib45","first-page":"217","article-title":"Relation of analgesic use to renal cancer: population-based findings","volume":"69","author":"McLaughlin","year":"1985","journal-title":"Natl. Cancer Inst. Monogr."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.105097_bib46","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105097_bib47","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/oncolo\/oyac269","article-title":"Characterization and management of adverse reactions from the CLEAR study in advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab","volume":"28","author":"Motzer","year":"2023","journal-title":"oncologist"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105097_bib48","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.105097_bib49","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105097_bib50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw.: JNCCN"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105097_bib51","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.105097_bib52","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.105097_bib53","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.105097_bib54","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105097_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010958","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma","volume":"13","author":"Moussa","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105097_bib56","first-page":"127","article-title":"Intestinal metastases from renal cell carcinoma: a rare cause of intestinal obstruction and bleeding","volume":"71","author":"Pavlakis","year":"2004","journal-title":"Mt. Sinai J. Med. N. Y."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105097_bib57","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S1470-2045(19)30510-8","article-title":"Renal cell carcinoma treatment after first-line combinations","volume":"20","author":"Porta","year":"2019","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105097_bib58","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105097_bib59","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105097_bib60","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.3390\/ijms26073431","article-title":"Kidney Injury molecule-1 as a biomarker for renal cancer: current insights and future perspectives-a narrative review","volume":"26","author":"Puia","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105097_bib61","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.eururo.2020.06.021","article-title":"Atezolizumab plus bevacizumab versus sunitinib for patients with untreated metastatic renal cell carcinoma and sarcomatoid features: a prespecified subgroup analysis of the IMmotion151 clinical trial","volume":"79","author":"Rini","year":"2021","journal-title":"Eur. Urol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105097_bib62","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105097_bib63","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105097_bib64","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00262-024-03897-x","article-title":"First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study","volume":"74","author":"Roviello","year":"2025","journal-title":"Cancer Immunol. Immunother. CII"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105097_bib65","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.euo.2023.07.003","article-title":"Real-world outcome of patients with advanced renal cell carcinoma and intermediate- or poor-risk international metastatic renal cell carcinoma database consortium criteria treated by immune-oncology combinations: differential effectiveness by risk group?","volume":"7","author":"Santoni","year":"2024","journal-title":"Eur. Urol. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105097_bib66","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1245\/s10434-014-4256-7","article-title":"Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors","volume":"22","author":"Santoni","year":"2015","journal-title":"Ann. Surg. Oncol."},{"issue":"36","key":"10.1016\/j.critrevonc.2025.105097_bib67","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/JCO.2018.79.1905","article-title":"Epidemiology and risk factors for kidney cancer","volume":"36","author":"Scelo","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105097_bib68","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.2147\/CMAR.S202017","article-title":"Ipilimumab and nivolumab as first-line treatment of patients with renal cell carcinoma: the evidence to date","volume":"12","author":"Sheng","year":"2020","journal-title":"Cancer Manag. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105097_bib69","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2025.105097_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118632","article-title":"Current updates and future perspectives on the management of renal cell carcinoma","volume":"264","author":"Singh","year":"2021","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105097_bib71","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.euf.2025.06.012","article-title":"KIM-1 as a prognostic marker in renal cell carcinoma","volume":"11","author":"Steiner","year":"2025","journal-title":"Eur. Urol. Focus"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105097_bib72","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1007\/s00432-022-04173-0","article-title":"Real world data on IO-based therapy for metastatic renal cell carcinoma","volume":"149","author":"St\u00fchler","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105097_bib73","article-title":"Novel pembrolizumab-based treatments as first-line therapy in advanced clear cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I\/II KEYMAKER-U03 trial","author":"Suarez","year":"2025","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105097_bib74","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105097_bib75","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/1078-0432.CCR-20-2063","article-title":"Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"27","author":"Tannir","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105097_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102745","article-title":"Treatment options in first-line metastatic renal carcinoma: a meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials","volume":"127","author":"Tucci","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105097_bib77","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/ijc.34126","article-title":"Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: the CABIR study","volume":"151","author":"Vano","year":"2022","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105097_bib78","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10456-014-9420-y","article-title":"Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions","volume":"17","author":"Vasudev","year":"2014","journal-title":"Angiogenesis"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105097_bib79","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41585-023-00818-y","article-title":"Diagnostic liquid biopsy biomarkers in renal cell cancer","volume":"21","author":"Zieren","year":"2024","journal-title":"Nat. Rev. Urol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:29:39Z","timestamp":1770035379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":79,"alternative-id":["S1040842825004858"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105097","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A daily clinical practice decision-making overview for the present metastatic renal cell carcinoma (mRCC) management landscape","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105097"}}